From Consensus Oncology to Individualized Biology

Every year brings new targeted therapies, immunotherapies, and genomic tests, yet far too many patients still cycle through multiple lines of treatment that don’t work, or work only briefly. Behind those statistics is a simple reality: most therapy decisions are still driven by generalized protocols and population-level evidence, not by the unique biology of each patient’s tumor. 1